Icagen CEO P. Kay Wagoner Honored by Women in Bio

Icagen, Inc. (NASDAQ: ICGN) announced that Dr. P. Kay Wagoner, President and CEO, was honored at the National Press Club in Washington DC during Women in Bio's Fifth Annual Dinner. Dr. Wagoner was honored for her excellence in capital raising for Icagen, Inc., the company she founded in 1992. Women in Bio is committed to helping women build and grow sustainable bioscience companies. The award to Dr. Wagoner was presented by Robbie Melton, Women in Bio's President. "I was surprised and honored to receive recognition from the Women in Bio organization, which was founded in 2002,” said Dr. Wagoner. "Organizations such as this support professional development for individuals seeking to advance their careers in the bioscience industry. I have been very fortunate to work with a talented group of people at Icagen, who are responsible in large measure for the success of our company." About Icagen Icagen, Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. Utilizing its proprietary know-how and integrated scientific and drug development capabilities, Icagen has identified multiple drug candidates that modulate ion channels. The Company’s four most advanced programs are: -  senicapoc for sickle cell disease, for which the Company is conducting a pivotal Phase III clinical trial;   -  lead compounds for epilepsy and neuropathic pain, for which the Company is conducting preclinical studies;   -  a lead compound for atrial fibrillation, for which the Company’s collaborator Bristol-Myers Squibb Company is conducting preclinical studies; and   -  lead compounds for dementia, including Alzheimer’s disease, for which the Company’s collaborator Astellas Pharma Inc. is conducting preclinical studies, and lead compounds for attention deficit/hyperactivity disorder, which were derived from the collaboration and for which the Company is conducting preclinical studies. Icagen is also conducting ongoing drug discovery programs focused on new therapeutics for pain and inflammatory disorders. Forward Looking Statements This press release contains forward-looking statements that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes,” "anticipates,” "plans,” "expects,” "intends,” and similar expressions are intended to identify forward-looking statements. Important factors that could cause actual results to differ materially from the expectations described in these forward-looking statements are set forth under the caption "Risk Factors” in the Company’s most recent Annual Report on Form 10-K, filed with the SEC on March 6, 2007. These risk factors include risks as to the Company’s ability to raise additional funding; the Company’s ability to maintain compliance with NASDAQ’s continued listing requirements; the Company’s history of net losses and how long the Company will be able to operate on its existing capital resources; whether the Company’s products will advance in the clinical trials process; the timing of such clinical trials; whether the results obtained in preliminary studies will be indicative of results obtained in clinical trials; whether the clinical trial results will warrant continued product development; whether and when, if at all, the Company’s products, including senicapoc, will receive approval from the U.S. Food and Drug Administration or equivalent regulatory agencies, and for which indications, and if such products receive approval, whether they will be successfully marketed; and the Company’s dependence on third parties, including manufacturers, suppliers and collaborators. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.